Literature DB >> 29214523

Haematopoietic Stem Cell Transplantation Arrests the Progression of Neurodegenerative Disease in Late-Onset Tay-Sachs Disease.

Karolina M Stepien1, Su Han Lum2, J Edmond Wraith3, Christian J Hendriksz4,5, Heather J Church3, David Priestman6, Frances M Platt6, Simon Jones3, Ana Jovanovic4, Robert Wynn2.   

Abstract

Tay-Sachs disease is a rare metabolic disease caused by a deficiency of hexosaminidase A that leads to accumulation of GM2 gangliosides predominantly in neural tissue. Late-onset Tay-Sachs disease variant is associated with a higher level of residual HexA activity. Treatment options are limited, and there are a few described cases who have undergone haematopoietic stem cell transplantation (HSCT) with variable outcome.We describe a case of a 23-year-old male patient who presented with a long-standing tremor since 7 years of age. He had gait ataxia, a speech stammer and swallowing problems. His condition had had a static course apart from his tremor that had been gradually deteriorating. Because of the deterioration in his neurological function, the patient had an uneventful, matched-sibling donor bone marrow transplant at the age of 15 years. Eight years post-HSCT, at the age of 23, he retains full donor engraftment, and his white cell beta-HexA of 191 nmol/mg/h is comparable to normal controls (in-assay control = 187). He continues to experience some intentional tremor that is tolerable for daily life and nonprogressive since HSCT.
CONCLUSION: HSCT is a potential treatment option which might arrest neurodegeneration in patients with LOTS.

Entities:  

Keywords:  Haematopoietic stem cell transplantation; Late onset; Tay-Sachs disease

Year:  2017        PMID: 29214523      PMCID: PMC6122053          DOI: 10.1007/8904_2017_76

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  33 in total

Review 1.  Neuropathology of late onset gangliosidoses. A review.

Authors:  K Suzuki
Journal:  Dev Neurosci       Date:  1991       Impact factor: 2.984

2.  Late-onset hexosaminidase A deficiency mimicking primary lateral sclerosis.

Authors:  Clecio Godeiro-Junior; Andre C Felicio; Vinicius Benites; Marco Antonio Chieia; Acary S B Oliveira
Journal:  Arq Neuropsiquiatr       Date:  2009-03       Impact factor: 1.420

3.  Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients.

Authors:  Orit Neudorfer; Gregory M Pastores; Bai J Zeng; John Gianutsos; Charles M Zaroff; Edwin H Kolodny
Journal:  Genet Med       Date:  2005-02       Impact factor: 8.822

Review 4.  Progressive muscular atrophy and other lower motor neuron syndromes of adults.

Authors:  Lewis P Rowland
Journal:  Muscle Nerve       Date:  2010-02       Impact factor: 3.217

5.  Effective gene therapy in an authentic model of Tay-Sachs-related diseases.

Authors:  M Begoña Cachón-González; Susan Z Wang; Andrew Lynch; Robin Ziegler; Seng H Cheng; Timothy M Cox
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-26       Impact factor: 11.205

6.  Bone marrow transplantation prolongs life span and ameliorates neurologic manifestations in Sandhoff disease mice.

Authors:  F Norflus; C J Tifft; M P McDonald; G Goldstein; J N Crawley; A Hoffmann; K Sandhoff; K Suzuki; R L Proia
Journal:  J Clin Invest       Date:  1998-05-01       Impact factor: 14.808

7.  Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation.

Authors:  M Jeyakumar; F Norflus; C J Tifft; M Cortina-Borja; T D Butters; R L Proia; V H Perry; R A Dwek; F M Platt
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

8.  NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin.

Authors:  Mylvaganam Jeyakumar; David A Smith; Ian M Williams; Mario Cortina Borja; David C A Neville; Terry D Butters; Raymond A Dwek; Frances M Platt
Journal:  Ann Neurol       Date:  2004-11       Impact factor: 10.422

9.  Retrovirus-mediated enzymatic correction of Tay-Sachs defect in transduced and non-transduced cells.

Authors:  J Guidotti; S Akli; L Castelnau-Ptakhine; A Kahn; L Poenaru
Journal:  Hum Mol Genet       Date:  1998-05       Impact factor: 6.150

10.  Late-onset Tay-Sachs disease: the spectrum of peripheral neuropathy in 30 affected patients.

Authors:  Barbara E Shapiro; Eric L Logigian; Edwin H Kolodny; Gregory M Pastores
Journal:  Muscle Nerve       Date:  2008-08       Impact factor: 3.217

View more
  5 in total

1.  Amyotrophy, cerebellar impairment and psychiatric disease are the main symptoms in a cohort of 14 Czech patients with the late-onset form of Tay-Sachs disease.

Authors:  Helena Jahnová; Helena Poupětová; Jitka Jirečková; Hana Vlášková; Eva Košťálová; Radim Mazanec; Alena Zumrová; Petr Mečíř; Zuzana Mušová; Martin Magner
Journal:  J Neurol       Date:  2019-05-10       Impact factor: 4.849

2.  [Progressive psychomotor regression for 2.5 years in a boy aged 5 years].

Authors:  Mao-Qiang Tian; Xiao-Xi Chen; Lei Li; Chang-Hui Lang; Juan Li; Jing Chen; Xiao-Hua Yu; Xiao-Mei Shu
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-06-15

Review 3.  Therapeutic Strategies For Tay-Sachs Disease.

Authors:  Jaqueline A Picache; Wei Zheng; Catherine Z Chen
Journal:  Front Pharmacol       Date:  2022-07-05       Impact factor: 5.988

Review 4.  New Approaches to Tay-Sachs Disease Therapy.

Authors:  Valeriya V Solovyeva; Alisa A Shaimardanova; Daria S Chulpanova; Kristina V Kitaeva; Lisa Chakrabarti; Albert A Rizvanov
Journal:  Front Physiol       Date:  2018-11-20       Impact factor: 4.566

5.  The GM2 gangliosidoses: Unlocking the mysteries of pathogenesis and treatment.

Authors:  Camilo Toro; Mosufa Zainab; Cynthia J Tifft
Journal:  Neurosci Lett       Date:  2021-08-25       Impact factor: 3.046

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.